Europe

Brexit and beyond: the challenges ahead for pharma
Brexit and beyond: the challenges ahead for pharma
Pharmaforum
Brexit
UK
Europe
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
CP Wire
Janssen
JNJ
Erleada
prostate cancer
Europe
Flag link:
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
Fierce Biotech
EMA
Europe
Brexit
UK
Amsterdam
Flag link:
US loses, EU wins as Chinese biotech investment shifts focus
US loses, EU wins as Chinese biotech investment shifts focus
Pharmaforum
China
Europe
biotech
Flag link:
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
KHN
biologics
United States
Europe
Flag link:
Merck bags adjuvant okay for Keytruda in melanoma
Merck bags adjuvant okay for Keytruda in melanoma
Pharmaforum
Merck
Europe
Keytruda
melanoma
Flag link:
The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry
The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry
Endpoints
pharma industry
UK
Europe
Brexit
Flag link:
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca
CP Wire
Clovis Oncology
Europe
Rubraca
Flag link:
How Pharmaceuticals Impact the Environment: EMA Revises Guideline
How Pharmaceuticals Impact the Environment: EMA Revises Guideline
RAPS.org
Europe
EMA
environmental concerns
Flag link:
Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS
Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS
Pharmaceutical Business Review
Novartis
Gilenya
Europe
Relapsing Remitting Multiple Sclerosis
Flag link:
FDA to Follow EMA With Move From London to Amsterdam
FDA to Follow EMA With Move From London to Amsterdam
RAPS.org
FDA
Amsterdam
EMA
Europe
Flag link:
European Commission Approves Kalydeco to Treat Cystic Fibrosis
European Commission Approves Kalydeco to Treat Cystic Fibrosis
CP Wire
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Europe
Flag link:
Luxturna cleared for sale in Europe, but payer support uncertain
Luxturna cleared for sale in Europe, but payer support uncertain
Biopharma Dive
Spark Therapeutics
Luxturna
Europe
gene therapy
Flag link:
Pharma hopes for best, fears the worst, as Brexit vote nears
Pharma hopes for best, fears the worst, as Brexit vote nears
Pharmaforum
Brexit
UK
Europe
pharma industry
Flag link:
Novartis/Spark’s sight gene therapy approved in EU
Novartis/Spark’s sight gene therapy approved in EU
Pharmaforum
Novartis
Spark Therapeutics
Luxturna
gene therapy
Europe
Flag link:
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Takeda
shareholders
Japan
M&A
Shire
Europe
Flag link:
Novartis focusing on cutting CAR-T costs ahead of EU launches
Novartis focusing on cutting CAR-T costs ahead of EU launches
Pharmaforum
Novartis
CAR-T
Europe
Flag link:
What a draft Brexit agreement means for the medical device industry
What a draft Brexit agreement means for the medical device industry
Emergo
devices
UK
Europe
Brexit
Flag link:
Edwards Lifesciences wins CE Mark for Sapien 3 Ultra TAVR
Edwards Lifesciences wins CE Mark for Sapien 3 Ultra TAVR
Mass Device
Edwards Lifesciences
CE Mark
Europe
Sapien 3
TAVR
devices
Flag link:
Biopharma may have to wait for Brexit details
Biopharma may have to wait for Brexit details
BioCentury
Brexit
Europe
UK
Flag link:

Pages